Clinical Trial Update: DTG/3TC Fixed Dose Formulations for the Maintenance of Virological Suppression in Children With HIV Infection Aged 2 to <15 Years Old [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial to maintain virological suppression in children aged 2 to under 15 with HIV; the study is active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Dovato (dolutegravir/lamivudine)

Snippet

Sponsor: PENTA Foundation | Conditions: HIV Infections | Phase 2, Phase 3 | Status: ACTIVE_NOT_RECRUITING